# Phage II Trial of Stathmin as Predictive Biomarker for TPF Induction Chemotherapy in OSCC

> **NCT03326947** · PHASE2 · RECRUITING · sponsor: **Shanghai Jiao Tong University School of Medicine** · enrollment: 60 (estimated)

## Conditions studied

- Neoplasm Neck

## Interventions

- **DRUG:** docetaxel, cisplatin and 5-fluorouracil

## Key facts

- **NCT ID:** NCT03326947
- **Lead sponsor:** Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-01-01
- **Primary completion:** 2026-01-01
- **Final completion:** 2027-01-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03326947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03326947, "Phage II Trial of Stathmin as Predictive Biomarker for TPF Induction Chemotherapy in OSCC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03326947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*